Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Accured Expenses (2016 - 2025)

Ultragenyx Pharmaceutical has reported Change in Accured Expenses over the past 10 years, most recently at $37.0 million for Q4 2025.

  • Quarterly Change in Accured Expenses fell 20.22% to $37.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.0 million through Dec 2025, down 48.94% year-over-year, with the annual reading at $24.0 million for FY2025, 48.94% down from the prior year.
  • Change in Accured Expenses was $37.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $45.1 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $57.4 million in Q2 2022 and troughed at -$48.5 million in Q1 2025.
  • The 5-year median for Change in Accured Expenses is $11.9 million (2021), against an average of $9.1 million.
  • The largest YoY upside for Change in Accured Expenses was 450.03% in 2021 against a maximum downside of 338.45% in 2021.
  • A 5-year view of Change in Accured Expenses shows it stood at $30.4 million in 2021, then dropped by 9.75% to $27.4 million in 2022, then crashed by 44.49% to $15.2 million in 2023, then soared by 204.72% to $46.4 million in 2024, then fell by 20.22% to $37.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Change in Accured Expenses are $37.0 million (Q4 2025), $45.1 million (Q3 2025), and -$9.7 million (Q2 2025).